These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

670 related items for PubMed ID: 27639246

  • 1. Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients.
    Heldenbrand S, Li C, Cross RP, DePiero KA, Dick TB, Ferguson K, Kim M, Newkirk E, Park JM, Sudaria-Kerr J, Tichy EM, Ueda KR, Weng R, Wisniewski J, Gabardi S.
    Transpl Infect Dis; 2016 Dec; 18(6):904-912. PubMed ID: 27639246
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of Low- Versus High-dose Valganciclovir for Prevention of Cytomegalovirus Disease in High-risk Renal Transplant Recipients.
    Gabardi S, Asipenko N, Fleming J, Lor K, McDevitt-Potter L, Mohammed A, Rogers C, Tichy EM, Weng R, Lee RA.
    Transplantation; 2015 Jul; 99(7):1499-505. PubMed ID: 25643140
    [Abstract] [Full Text] [Related]

  • 3. Low-dose valganciclovir prophylaxis for cytomegalovirus in intermediate-risk (R+) renal transplant recipients: Single-center experience.
    Khan S, Fischman C, Huprikar S.
    Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28940831
    [Abstract] [Full Text] [Related]

  • 4. Low-dose valganciclovir for cytomegalovirus prophylaxis in intermediate-risk liver transplantation recipients.
    Khan S, Sullivan T, Ali M, Dunn D, Patel G, Huprikar S.
    Liver Transpl; 2018 May; 24(5):616-622. PubMed ID: 29500912
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M, VIPP Study Group.
    Transplantation; 2012 Jan 15; 93(1):61-8. PubMed ID: 22094954
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cytomegalovirus Infection in Pediatric Renal Transplantation and the Impact of Chemoprophylaxis With (Val-)Ganciclovir.
    Höcker B, Zencke S, Krupka K, Fichtner A, Pape L, Dello Strologo L, Guzzo I, Topaloglu R, Kranz B, König J, Bald M, Webb NJ, Noyan A, Dursun H, Marks S, Yalcinkaya F, Thiel F, Billing H, Pohl M, Fehrenbach H, Bruckner T, Tönshoff B.
    Transplantation; 2016 Apr 15; 100(4):862-70. PubMed ID: 26736017
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients.
    Park JM, Lake KD, Arenas JD, Fontana RJ.
    Liver Transpl; 2006 Jan 15; 12(1):112-6. PubMed ID: 16382458
    [Abstract] [Full Text] [Related]

  • 12. Low-dose valganciclovir prohylaxis is efficacious and safe in cytomegalovirus seropositive heart transplant recipients with anti-thymocyte globulin.
    Eriksson M, Jokinen JJ, Söderlund S, Hämmäinen P, Lommi J, Lemström K.
    Transpl Infect Dis; 2018 Jun 15; 20(3):e12868. PubMed ID: 29512249
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and Safety of Low-Dose Versus Standard-Dose Valganciclovir for Prevention of Cytomegalovirus Disease in Intermediate-Risk Kidney Transplant Recipients.
    Halim MA, Al-Otaibi T, Gheith O, Adel H, Mosaad A, Hasaneen AA, Zakaria Z, Makkeya Y, Said T, Nair P.
    Exp Clin Transplant; 2016 Oct 15; 14(5):526-534. PubMed ID: 27310254
    [Abstract] [Full Text] [Related]

  • 14. Comparison of standard versus low-dose valganciclovir regimens for cytomegalovirus prophylaxis in high-risk liver transplant recipients.
    Bixby AL, Fitzgerald L, Park JM, Kaul D, Tischer S.
    Transpl Infect Dis; 2021 Oct 15; 23(5):e13713. PubMed ID: 34428337
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cytomegalovirus infection in heart transplantation: A single center experience.
    Echenique IA, Angarone MP, Rich JD, Anderson AS, Stosor V.
    Transpl Infect Dis; 2018 Aug 15; 20(4):e12896. PubMed ID: 29602266
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Low dose valganciclovir as cytomegalovirus prophylaxis in post-renal transplant recipients induced with alemtuzumab: A single-center study.
    Korneffel K, Mitro G, Buschor K, Rees M, Ortiz J.
    Transpl Immunol; 2019 Oct 15; 56():101226. PubMed ID: 31344441
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Impact of donor and recipient cytomegalovirus serology on long-term survival of lung transplant recipients.
    Mabilangan C, Preiksaitis J, Cervera C, University of Alberta Cardiothoracic Transplant Group.
    Transpl Infect Dis; 2018 Oct 15; 20(5):e12964. PubMed ID: 29981174
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.